Chelsee Jensen, PharmD, pharmaceutical formulary manager at the Mayo Clinic, explains what health organizations and health systems can do to better manage and instill confidence in biosimilars.
Chelsee Jensen, PharmD, pharmaceutical formulary manager at the Mayo Clinic, shares actions that can help improve patient confidence in biosimilars and weighs in on whether interchangeable ranibizumab biosimilars will impact how people view interchangeability designations.
Transcript
What can health organizations do to ensure that biosimilars are well-managed and that patients are confident in their utilization?
Jensen: I believe that to ensure that your organization remains engaged is to have timely report outs of how are we utilizing biosimilars? How are we saving money? How are our patients doing? Have there been any safety or efficacy signals reported back? Again, in our experience, there really have not. But continuing to keep those people engaged—How was the prior authorization process working? Are our payer landscaping changes? Are their contracting changes?—keeping all those players engaged is going to really help promote...the continued use of biosimilars, and again, reduction of health care expenditures overall.
How can health systems be active members in the fight for better biosimilar legislation and policies?
Jensen: I would say really continuing to advocate and lobby, especially for real-time benefit checks on medical benefit. I think that would significantly reduce burden at many, many levels. So, continuing to push for that is really important, as well as CMS to keep in check of are they being transparent and what are Medicare Part D plans doing vs Medicare Part B plans doing? I know there was an Office of Inspector General report released in March of 2022 that showed a lot of Part D plans actually were not incentivizing or even covering biosimilars compared to the reference product.
So, I think as we especially change to this more PBM [pharmacy benefit manager] space, in 2023 and beyond, it's really important to keep in focus of how those Part D and B plans covering biosimilars. Are they incentivizing them? And if we are not seeing health care savings, again, to take a better look on how those are placed on formulary tiers.
Recently, Cimerli, a ranibizumab biosimilar, launched on the US market with an interchangeability designation. However, because it is not a product dispensed in pharmacies, the designation will not apply. How might the market introduction of this product with this designation impact how stakeholders view interchangeability and the safety of biosimilars overall?
Jensen: I truly don't think there's going to be much of an impact on how people view safety of biosimilars or interchangeability. I think it's truly going to come down to what are the covered indications and how are they contracting? So, maybe a health system might have to carry both the Byooviz [another ranibizumab biosimilar] and Cimerli because they didn't get favorable contracting and driving towards one, where you have patients who are covered by 1 indication and then the other product for the other indication.
So, I think it's going to create a little bit of a management issue, but again, it's going to come down to competitive contracting. However, I do believe that providers will naturally move away from reference Lucentis.
Ranibizumab Biosimilar Shows Reduced Efficacy vs Aflibercept in nAMD
April 3rd 2025The ranibizumab biosimilar Ongavia exhibited significantly less improvement in visual acuity and retinal thickness compared with aflibercept (Eylea) in treating neovascular age-related macular degeneration (nAMD), highlighting a potential trade-off between economic savings and clinical efficacy.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Real-World Data Confirm Safety of Switching Between Ranibizumab Biosimilars
March 19th 2025Patients with diabetic macular edema previously treated with a ranibizumab biosimilar in India experience comparable safety and efficacy after being switched to another ranibizumab biosimilar, demonstrating real-world safety of biosimilar-to-biosimilar switching.
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.